Supported by the National Key Research and Development Program of China(Nos.2018YFC1106100,2018YFC1106102);the National Natural Science Foundation of China(Nos.21661162001,21673139,51690151,51473093,51973112);the Special Program for Collaborative Innovation in Shanghai University of Medicine&Health Sciences,China(No.SPCI-17-15-001);the Program of Shanghai Medical Professionals Across Subject Funds,China(No.YG2016MS74).
Herein,we report a geometrically well-defined prism assembled by two floxuridine(F)integrated RNA strands as a precise nanomedicine for chemodrug delivery.Owing to the similarity between chemotherapeutic F and uridine...
supported by a grant from the National High Technology Research and Development Program (863 Program), P. R. China (No. 2012AA022701)
The survival of most patients with both unresectable hepatic and pulmonary metastases of colorectal cancer is poor. In this retrospective study, we investigated the efficacy of computed tomography(CT)-guided radiofreq...
AIM:To investigate the efficacy of hepatic arterial infusion chemotherapy(HAIC) using floxuridine(FUDR) in patients with advanced hepatocellular carcinoma(HCC) confined to the liver.METHODS:Thirty-four patients who ha...
Projected supported by the Education Committee of Zhejiang Province; China (No20030584).
AIM: To establish a high pressure liquid chromatography (HPLC) method for determination of the concentration of gemcitabine (dFdC) and its metabolite(dFdU) in human plasma. METHODS: Plasma 1.0 mL spikedwith floxuridi...